Filament Health debuts on the NEO exchange as natural-focused psychedelic group

0 Просмотры
Издатель
Filament Health Corp (NEO:FH) CEO Ben Lightburn joined Proactive to discuss the Vancouver, Canada-based group's new listing on the NEO Exchange, where its shares have begun trading starting June 24th.

Lightburn says the naturally-focused psychedelic drug discovery and extraction technology company is going to be the first group to administer naturally extracted psychedelic compounds in an FDA approved Phase 1 clinical trial, as well as administering a compound from mushrooms that is not psilocybin.

What's more, the group will soon begin a Phase 2 study to to treat depression with its psilocybin compared to Ketamine.
Категория
приключения
Комментариев нет.
Яндекс.Метрика